ONMD vs PHVS vs NVCR vs KALV

For growth investors, OneMedNet Corporation (ONMD) is the stronger pick with 111.

4% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). Analysts rate Pharvaris N. V. (PHVS) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Pharvaris N.

V. (PHVS) delivered a total return of +31. 2%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: KALV returned +154. 5% versus ONMD's -90. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), OneMedNet Corporation (ONMD) is the lower-risk stock at 0.

37β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 491% more volatile than ONMD relative to the S&P 500. On balance sheet safety, Pharvaris N. V. (PHVS) carries a lower debt/equity ratio of 0% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), OneMedNet Corporation (ONMD) is pulling ahead at 111.

4% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: OneMedNet Corporation grew EPS 83. 3% year-over-year, compared to -7. 3% for KalVista Pharmaceuticals, Inc.. Over a 3-year CAGR, NVCR leads at 6. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Pharvaris N.

V. (PHVS) is the more profitable company, earning 0. 0% net margin versus -1391. 1% for KalVista Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PHVS leads at 0. 0% versus -1343. 0% for KALV. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, OneMedNet Corporation (ONMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

37)). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ONMD: -90. 1%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ONMD is a small-cap high-growth stock; PHVS is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; KALV is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.